Q1 EPS Estimates for Mersana Therapeutics Cut by Wedbush
Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) - Research analysts at Wedbush reduced their Q1 2025 EPS estimates for shares of Mersana Therapeutics in a report issued on Monday, March 3rd. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.25) per sh.
Publicado el: 2025-03-07 12:18:57
Autor: lulegacy, Fuente: lulegacy
Compartir: 
